Table 3.
Factors associated with a positive QFT result at visit 1 using different definitions of QFT positivity
| Definition 1 | Definition 2a | Definition 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (≥0.2 IU/ml) | (≥0.35 IU/ml) | (≥0.7 IU/ml) | |||||||
| QFT positive (n) | total (n) | Adjusted OR (95%CI)b |
QFT positive (n) |
total (n) | Adjusted OR (95%CI)b |
QFT positive (n) | total (n) | Adjusted OR (95%CI)b |
|
| Both countries | |||||||||
| Total | 1361 (68) | 1988 | 1243 (63) | 1968 | 1103 (57) | 1951 | |||
| HIV status | |||||||||
| HIV negative | 1026 (72) | 1417 | 1 | 942 (67) | 1402 | 1 | 839 (60) | 1390 | 1 |
| HIV positive, no ARV | 288 (58) | 496 | 0.5 (0.4–0.6) | 258 (53) | 491 | 0.5 (0.4–0.6) | 229 (47) | 489 | 0.5 (0.4–0.6) |
| HIV positive & ARV | 30 (55) | 55 | 0.4 (0.2–0.8) | 28 (51) | 55 | 0.4 (0.3–0.8) | 21 (40) | 53 | 0.4 (0.2–0.8) |
| Unknown | 17 (85) | 20 | 15 (75) | 20 | 14 (74) | 19 | |||
| Zambia | |||||||||
| Total | 735 (62) | 1180 | 669 (57) | 1164 | 599 (52) | 1150 | |||
| HIV status | |||||||||
| HIV negative | 529 (65) | 808 | 1 | 484 (61) | 797 | 1 | 435 (55) | 788 | 1 |
| HIV positive, no ARV | 176 (55) | 321 | 0.5 (0.4–0.7) | 158 (50) | 316 | 0.5 (0.4–0.7) | 142 (45) | 314 | 0.5 (0.4–0.7) |
| HIV positive & ARV | 18 (49) | 37 | 0.4 (0.2–0.8) | 16 (43) | 37 | 0.4 (0.2–0.8) | 12 (34) | 35 | 0.3 (0.2–0.7) |
| Unknown | 12 (86) | 14 | 11 (79) | 14 | 10 (77) | 13 | |||
| Region by TST prevalence | |||||||||
| Lusaka, high TST | 249 (68) | 369 | 1 | 234 (64) | 363 | 1 | 217 (60) | 359 | 1 |
| Urban, high TST | 207 (63) | 331 | 0.6 (0.4–0.9) | 186 (57) | 326 | 0.6 (0.4–0.9) | 158 (49) | 322 | 0.6 (0.4–0.9) |
| Urban, low TST | 205 (57) | 357 | 0.5 (0.4–0.8) | 181 (52) | 350 | 0.5 (0.4–0.7) | 164 (48) | 345 | 0.5 (0.4–0.7) |
| Rural, low TST | 74 (58) | 127 | 0.5 (0.3–0.9) | 68 (54) | 125 | 0.6 (0.3–0.9) | 60 (48) | 124 | 0.6 (0.3–0.9) |
| South Africa | |||||||||
| Total | 626 (77) | 808 | 574 (71) | 804 | 504 (63) | 801 | |||
| HIV status | |||||||||
| HIV negative | 497 (82) | 609 | 1 | 458 (76) | 605 | 1 | 404 (67) | 602 | 1 |
| HIV positive, no ARV | 112 (64) | 175 | 0.4 (0.3–0.6) | 100 (57) | 175 | 0.4 (0.3–0.6) | 87 (50) | 175 | 0.4 (0.3–0.6) |
| HIV positive & ARV | 12 (67) | 18 | 0.7 (0.2–2.0) | 12 (67) | 18 | 0.7 (0.2–2.0) | 9 (50) | 18 | 0.7 (0.2–2.1) |
| Unknown | 5 (83) | 6 | 4 (67) | 6 | 4 (67) | 6 | |||
| TST prevalence | |||||||||
| High | 366 (80) | 460 | 1 | 338 (74) | 457 | 1 | 298 (65) | 455 | 1 |
| Low | 260 (75) | 348 | 0.7 (0.5–1.0) | 236 (68) | 347 | 0.7 (0.5–1.0) | 206 (60) | 346 | 0.7 (0.5–1.0) |
aTable A1, additional file, presents unadjusted odds ratios, estimates for sex and age, and p-values
b Adjusted models also included sex, age and HH intervention (yes/no). All variables were simultaneously added to the regression models